4//SEC Filing
Derakhshan Behrad 4
Accession 0001562180-25-001024
CIK 0001710072other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 4:37 PM ET
Size
9.2 KB
Accession
0001562180-25-001024
Insider Transaction Report
Form 4
Derakhshan Behrad
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-05$1.93/sh+10,000$19,300→ 26,837 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-05−10,000→ 92,929 totalExercise: $1.93From: 2024-12-03Exp: 2030-12-15→ Common Stock (10,000 underlying) - Sale
Common Stock
2025-02-05$30.03/sh−10,000$300,300→ 16,837 total
Footnotes (3)
- [F1]Includes 1,716 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024.
- [F3]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Edgewise Therapeutics, Inc.
CIK 0001710072
Entity typeother
Related Parties
1- filerCIK 0001853109
Filing Metadata
- Form type
- 4
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 4:37 PM ET
- Size
- 9.2 KB